With Portfolio Review Nearing End, Integration Issues Take a Toll on Invitrogen's Q3 Results | GenomeWeb
Despite reporting 7-percent revenue growth for the third quarter last week, Invitrogen failed to match its own — and Wall Street’s — expectations, and management acknowledged that challenges integrating the many acquisitions made over the previous two years have played a role in its recent struggles.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.